Red blood cell transfusion in sickle cell patients
Autor(a) principal: | |
---|---|
Data de Publicação: | 2019 |
Outros Autores: | , , |
Tipo de documento: | Artigo |
Idioma: | por |
Título da fonte: | Scire Salutis |
Texto Completo: | https://sustenere.inf.br/index.php/sciresalutis/article/view/CBPC2236-9600.2019.001.0007 |
Resumo: | Sickle cell anemia is a prevalent disease in Brazil, and is characterized by a genetic mutation that causes deformity in the red blood cells of the carrier, causing several problems. A good part of these patients need frequent transfusions to treat complications of the disease, but over time there may be complications resulting from these transfusions, which makes the use of this therapy very careful. But why can sickle cell patients have problems with transfusion therapy? Due to the frequency of transfusions, the sickle cell patient may be alloimmunized against antigens from various blood group systems. The best way to prevent this type of reaction is to perform red cell phenotyping for compatibility testing. The present study aimed to address the red blood cell transfusion in sickle cell patients, also listing the reactions that may occur due to this therapy and the procedures that should be taken to avoid such reactions, also addressing the role of the biomedical in this process. It is a literary research conducted based on national and international scientific articles, monographs, laws and books that were selected using as a criterion the approach of the chosen theme. We used as research sources the sites SCIELO (Scientific Electronic Library Online), Pubmed, Virtual Library of the Ministry of Health and books present in the physical and virtual library of the Educational Institute Santa Catarina (IESC). Transfusion therapy is a great option to treat the complications of sickle cell anemia, but measures should be used to prevent post-transfusion problems. |
id |
ESS-1_30806ee44e3d7ba46a9a26c5deeb3fde |
---|---|
oai_identifier_str |
oai:ojs.pkp.sfu.ca:article/2663 |
network_acronym_str |
ESS-1 |
network_name_str |
Scire Salutis |
repository_id_str |
|
spelling |
Red blood cell transfusion in sickle cell patientsTransfusão de hemácias em pacientes falcêmicosAnemia FalciformeAloimunizaçãoTransfusãoSickle cell anemiaAlloimmunizationTransfusionSickle cell anemia is a prevalent disease in Brazil, and is characterized by a genetic mutation that causes deformity in the red blood cells of the carrier, causing several problems. A good part of these patients need frequent transfusions to treat complications of the disease, but over time there may be complications resulting from these transfusions, which makes the use of this therapy very careful. But why can sickle cell patients have problems with transfusion therapy? Due to the frequency of transfusions, the sickle cell patient may be alloimmunized against antigens from various blood group systems. The best way to prevent this type of reaction is to perform red cell phenotyping for compatibility testing. The present study aimed to address the red blood cell transfusion in sickle cell patients, also listing the reactions that may occur due to this therapy and the procedures that should be taken to avoid such reactions, also addressing the role of the biomedical in this process. It is a literary research conducted based on national and international scientific articles, monographs, laws and books that were selected using as a criterion the approach of the chosen theme. We used as research sources the sites SCIELO (Scientific Electronic Library Online), Pubmed, Virtual Library of the Ministry of Health and books present in the physical and virtual library of the Educational Institute Santa Catarina (IESC). Transfusion therapy is a great option to treat the complications of sickle cell anemia, but measures should be used to prevent post-transfusion problems.A anemia falciforme é uma doença prevalente no Brasil, e é caracterizada por uma mutação genética que provoca uma deformidade nas hemácias do portador, causando diversos problemas. Uma boa parte desses pacientes necessitam de transfusões frequentes para tratamento de complicações da doença, porém, ao longo do tempo podem surgir complicações resultantes dessas transfusões, o que torna o uso dessa terapia bastante criteriosa. Mas por que o paciente falciforme pode apresentar problemas com a terapia transfusional? Devido a frequência de transfusões, o paciente falcêmico pode sofrer uma aloimunização contra antígenos de vários sistemas de grupos sanguíneos. A melhor forma de prevenir esse tipo de reação é realizando a fenotipagem das hemácias para teste de compatibilidade. O presente estudo teve como objetivo abordar sobre a transfusão de hemácias em pacientes falcêmicos, elencando também as reações que podem ocorrer em função dessa terapia e os procedimentos que devem ser tomados para evitar tais reações, abordando também o papel do biomédico nesse processo. Trata-se de uma pesquisa literária realizada com base em artigos científicos nacionais e internacionais, monografias, leis e livros que foram selecionados utilizando como critério a abordagem do tema escolhido. Foram utilizados como fontes de pesquisa os sites SCIELO (Scientific Electronic Library Online), Pubmed, Biblioteca Virtual do Ministério da Saúde e livros presentes na biblioteca física e virtual do Instituto Educacional Santa Catarina (IESC). A terapia transfusional é uma ótima opção de tratamento das complicações da anemia falciforme, porém devem ser utilizadas medidas para prevenir os problemas pós-transfusionais.Sustenere Publishing2019-06-20info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://sustenere.inf.br/index.php/sciresalutis/article/view/CBPC2236-9600.2019.001.000710.6008/CBPC2236-9600.2019.001.0007Scire Salutis; Vol. 9 No. 1 (2019): Scire Salutis - Out, Nov, Dez 2018, Jan 2019; 50-61Scire Salutis; Vol. 9 Núm. 1 (2019): Scire Salutis - Out, Nov, Dez 2018, Jan 2019; 50-61Scire Salutis; v. 9 n. 1 (2019): Scire Salutis - Out, Nov, Dez 2018, Jan 2019; 50-612236-9600reponame:Scire Salutisinstname:Companhia Brasileira de Produção Científica (CBPC)instacron:ESSporhttps://sustenere.inf.br/index.php/sciresalutis/article/view/CBPC2236-9600.2019.001.0007/1499Copyright (c) 2019 Scire Salutisinfo:eu-repo/semantics/openAccessBarros, Rawanderson Ferreira LimaSilva, Roniel Resplandes daMota, Mara Soares de AlmeidaAndrade, Simone Pôssas2020-01-08T10:56:39Zoai:ojs.pkp.sfu.ca:article/2663Revistahttps://sustenere.co/index.php/sciresalutisONGhttps://sustenere.co/index.php/sciresalutis/oai||carlos@arvore.org.br2236-96002236-9600opendoar:2020-01-08T10:56:39Scire Salutis - Companhia Brasileira de Produção Científica (CBPC)false |
dc.title.none.fl_str_mv |
Red blood cell transfusion in sickle cell patients Transfusão de hemácias em pacientes falcêmicos |
title |
Red blood cell transfusion in sickle cell patients |
spellingShingle |
Red blood cell transfusion in sickle cell patients Barros, Rawanderson Ferreira Lima Anemia Falciforme Aloimunização Transfusão Sickle cell anemia Alloimmunization Transfusion |
title_short |
Red blood cell transfusion in sickle cell patients |
title_full |
Red blood cell transfusion in sickle cell patients |
title_fullStr |
Red blood cell transfusion in sickle cell patients |
title_full_unstemmed |
Red blood cell transfusion in sickle cell patients |
title_sort |
Red blood cell transfusion in sickle cell patients |
author |
Barros, Rawanderson Ferreira Lima |
author_facet |
Barros, Rawanderson Ferreira Lima Silva, Roniel Resplandes da Mota, Mara Soares de Almeida Andrade, Simone Pôssas |
author_role |
author |
author2 |
Silva, Roniel Resplandes da Mota, Mara Soares de Almeida Andrade, Simone Pôssas |
author2_role |
author author author |
dc.contributor.author.fl_str_mv |
Barros, Rawanderson Ferreira Lima Silva, Roniel Resplandes da Mota, Mara Soares de Almeida Andrade, Simone Pôssas |
dc.subject.por.fl_str_mv |
Anemia Falciforme Aloimunização Transfusão Sickle cell anemia Alloimmunization Transfusion |
topic |
Anemia Falciforme Aloimunização Transfusão Sickle cell anemia Alloimmunization Transfusion |
description |
Sickle cell anemia is a prevalent disease in Brazil, and is characterized by a genetic mutation that causes deformity in the red blood cells of the carrier, causing several problems. A good part of these patients need frequent transfusions to treat complications of the disease, but over time there may be complications resulting from these transfusions, which makes the use of this therapy very careful. But why can sickle cell patients have problems with transfusion therapy? Due to the frequency of transfusions, the sickle cell patient may be alloimmunized against antigens from various blood group systems. The best way to prevent this type of reaction is to perform red cell phenotyping for compatibility testing. The present study aimed to address the red blood cell transfusion in sickle cell patients, also listing the reactions that may occur due to this therapy and the procedures that should be taken to avoid such reactions, also addressing the role of the biomedical in this process. It is a literary research conducted based on national and international scientific articles, monographs, laws and books that were selected using as a criterion the approach of the chosen theme. We used as research sources the sites SCIELO (Scientific Electronic Library Online), Pubmed, Virtual Library of the Ministry of Health and books present in the physical and virtual library of the Educational Institute Santa Catarina (IESC). Transfusion therapy is a great option to treat the complications of sickle cell anemia, but measures should be used to prevent post-transfusion problems. |
publishDate |
2019 |
dc.date.none.fl_str_mv |
2019-06-20 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://sustenere.inf.br/index.php/sciresalutis/article/view/CBPC2236-9600.2019.001.0007 10.6008/CBPC2236-9600.2019.001.0007 |
url |
https://sustenere.inf.br/index.php/sciresalutis/article/view/CBPC2236-9600.2019.001.0007 |
identifier_str_mv |
10.6008/CBPC2236-9600.2019.001.0007 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.none.fl_str_mv |
https://sustenere.inf.br/index.php/sciresalutis/article/view/CBPC2236-9600.2019.001.0007/1499 |
dc.rights.driver.fl_str_mv |
Copyright (c) 2019 Scire Salutis info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
Copyright (c) 2019 Scire Salutis |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Sustenere Publishing |
publisher.none.fl_str_mv |
Sustenere Publishing |
dc.source.none.fl_str_mv |
Scire Salutis; Vol. 9 No. 1 (2019): Scire Salutis - Out, Nov, Dez 2018, Jan 2019; 50-61 Scire Salutis; Vol. 9 Núm. 1 (2019): Scire Salutis - Out, Nov, Dez 2018, Jan 2019; 50-61 Scire Salutis; v. 9 n. 1 (2019): Scire Salutis - Out, Nov, Dez 2018, Jan 2019; 50-61 2236-9600 reponame:Scire Salutis instname:Companhia Brasileira de Produção Científica (CBPC) instacron:ESS |
instname_str |
Companhia Brasileira de Produção Científica (CBPC) |
instacron_str |
ESS |
institution |
ESS |
reponame_str |
Scire Salutis |
collection |
Scire Salutis |
repository.name.fl_str_mv |
Scire Salutis - Companhia Brasileira de Produção Científica (CBPC) |
repository.mail.fl_str_mv |
||carlos@arvore.org.br |
_version_ |
1793890277762531328 |